(Q36482313)

14 August 2017

Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia (English)

1 reference

14 August 2017

1 reference

Enterococcus faecium

1 reference

Kvirikadze N

1

1 reference

14 August 2017

Suseno M

2

1 reference

14 August 2017

Vescio T

3

1 reference

14 August 2017

Kaminer L

4

1 reference

14 August 2017

Singh K

5

1 reference

14 August 2017

1 January 2006

1 reference

Scandinavian Journal of Infectious Diseases

14 August 2017

1 reference

14 August 2017

38

1 reference

14 August 2017

4

1 reference

14 August 2017

290-292

1 reference

Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality

14 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Vancomycin-resistant enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Vancomycin-resistant enterococci: mechanisms and clinical observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Quinupristin-dalfopristin and linezolid: evidence and opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Resistance studies with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Novel agents for the treatment of resistant Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540500434687

10.1080/00365540500434687

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference